RESUMEN
Elliptinium acetate (EA) is a new anti-cancer compound displaying cytostatic activity against various malignancies including hepatoma. Using 3 hepatoma cell lines, we compared the in vitro activity of doxorubicin (reference drug), of EA and of conjugates made up with this latter drug and monoclonal antibodies (MAbs). The linkage was performed by a direct oxidation method. Specific immunoconjugates were prepared with an anti-alphafetoprotein (AFP) MAb (AF01) or its Fab fragment (Fab AF01). Non-specific conjugates were obtained with an anti-thyroglobulin MAb (TG01) or its Fab (Fab TG01). Direct membrane injury (51Cr-release), DNA and protein synthesis as well as AFP release were investigated for all compounds. Free EA displayed only weak activity on DNA and protein synthesis, at 10-fold higher molar concentration than doxorubicin. Conjugation of EA with whole AF01 allowed significant potentiation of protein synthesis inhibition without affecting the 3 other tests. In contrast, Fab AF01 x EA conjugates displayed a marked effect in the 4 tests; in particular, this conjugate was at least 100 times more efficient than any other compound when tested in the 51Cr-release test. Neither Fab AF01 nor free EA alone or in combination exhibited such an effect. Fab TG01 x EA conjugate was not directly cytotoxic but potentiated inhibition of DNA and protein synthesis between 2- and 10-fold. The mechanism of the direct cytotoxic effect of anti-AFP Fab x EA conjugate, which has never been described in any other immunodrug model, was investigated.
Asunto(s)
Alcaloides/farmacología , Anticuerpos Monoclonales/farmacología , Antineoplásicos/farmacología , Carcinoma Hepatocelular/tratamiento farmacológico , Elipticinas/farmacología , Fragmentos Fab de Inmunoglobulinas , Neoplasias Hepáticas/tratamiento farmacológico , alfa-Fetoproteínas/inmunología , Línea Celular , Fenómenos Químicos , Química , ADN de Neoplasias/efectos de los fármacos , Combinación de Medicamentos , Humanos , Fragmentos Fab de Inmunoglobulinas/inmunologíaRESUMEN
Antibodies directed against elliptinium acetate, a quaternary ammonium compound with antineoplastic activity in man, were obtained in rabbits, after conjugation of the drug with haemocyanin. These antibodies are specific for the quaternary ammonium structure. However, the recognition of the drug can be markedly decreased (ten-fold) by changing the associated counterion. These observations were extended to other ellipticine derivatives that exist in two forms: acetate and chloride. In each case, the recognition of the acetate form was 7-11-fold higher than that of the chloride form. These results could be explained by high-energy strengths existing between the cation and the anion, resulting in a paired-ion antigen. This represents the first identification of antibodies directed to a paired-ion structure, with specificity for both the cation and anion used for immunization. Such results are relevant in the construction of immunoassays for quaternary ammonium compounds.
Asunto(s)
Alcaloides/inmunología , Elipticinas/inmunología , Compuestos de Amonio Cuaternario/inmunología , Animales , Afinidad de Anticuerpos , Elipticinas/análisis , Hemocianinas/inmunología , Humanos , Conejos , Radioinmunoensayo , Sales (Química) , Relación Estructura-ActividadRESUMEN
The immune response to a 37-amino acid synthetic peptide analogous to the carboxyl-terminal part (109-145) of the human chorionic gonadotropin beta subunit (beta hCG) was studied with monoclonal antibodies selected from 31 cell fusion experiments. Analysis of the immunogenic determinants borne on the synthetic peptide (CTP) showed a prevailing response to two immunodominant regions. The first was located on the 110-116 amino acid sequence of the CTP which is also the most hydrophilic region: 50% of anti-CTP antibodies selected for their high binding to 125I beta hCG were directed to this sequence. A second immunodominant portion was recognized by four antibodies, and comprised amino acids 134 to 139, representing a highly O-glycosylated region on the native protein. Moreover, a unique antibody designated FB13 bound to a region located on the last seven amino acids (139-145) of beta hCG. Finally, a hypothetical conformational determinant was recognized by antibody FB02 within the 121-145 region. Thus, the immune response to CTP was directed against two major and two minor regions. These antigenic determinants were demonstrated to be accessible for antibody binding on both the hCG molecule and its beta subunit. Localization of these epitopes suggests a relationship between the hydrophilicity and the immunological potency of different CTP regions.
Asunto(s)
Gonadotropina Coriónica/inmunología , Epítopos/análisis , Fragmentos de Péptidos/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Monoclonales/inmunología , Gonadotropina Coriónica Humana de Subunidad beta , Ratones , Ratones Endogámicos BALB C , Fragmentos de Péptidos/síntesis químicaRESUMEN
In order to elucidate the immune-mediated hemolytic disease induced in man by elliptinium acetate, a quaternary ammonium compound with antineoplastic activity, polyclonal antibodies directed against this hapten were raised in rabbits. The coupling step between drug and carrier was performed according to a putative human in vivo hapten conjugation mechanism. Structure-activity relationships of the resulting IgG were compared with the epitope site recognized by human anti-elliptinium IgM by using a panel of twelve elliptinium acetate analogues. Although both antibodies were directed principally against the quaternary ammonium ion, a poor correlation between the cross-reactivity indices was obtained. In fact, it appeared that both antibodies recognized specifically the ammonium group plus different regions of the molecule: the indole ring for human antibodies, the N-alkyl group and its vicinity for rabbit ones. The specificity of the obtained rabbit polyclonal antisera is discussed, with regard to the conjugation mechanism of the drug occurring in man.
Asunto(s)
Alcaloides/inmunología , Elipticinas/inmunología , Anemia Hemolítica/inducido químicamente , Anemia Hemolítica/inmunología , Animales , Reacciones Cruzadas , Elipticinas/efectos adversos , Humanos , Inmunoglobulina G/inmunología , Inmunoglobulina M/inmunología , Conejos , Relación Estructura-ActividadRESUMEN
Monoclonal antibodies recognizing the 4-amino-7-chloro-quinoline (ACQ) structure, which represents the backbone of the 4-amino-quinoline antimalarial drugs, were obtained in mice, after injection of ACQ coupled to hemocyanin via the glutaraldehyde method. The resulting antibodies show a definite specificity to this hapten, but react better with compounds substituted on the exocyclic amino group in 4. It is postulated that the quinoline ring is not sufficient for the reaction with the antibodies, and that an enlarged structure, which is given by the bridge used to link hapten and carrier, entails an important increase (1000-fold) in the apparent affinity. The striking similarities between this bridge and the lateral chains of the antimalarial drugs are accountable for this enhanced recognition. This result allows us to indicate that in some instances, the bridge-structure of the immunogen should be positively involved in the epitope. This observation may become useful in the conception of immunogens, aiming to obtain antibodies directed against some lipophilic and small-sized haptens.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Antimaláricos/inmunología , Cloroquina/inmunología , Haptenos/inmunología , Aminoquinolinas/inmunología , Animales , Anticuerpos Monoclonales/biosíntesis , Afinidad de Anticuerpos , RatonesRESUMEN
Among the antimalarial drugs, chloroquine (CLQ) and 4-aminoquinoline derivatives display important interferences with biological membranes. The present study reports the effects of CLQ on dihydropyridine binding sites, measured in the heart of rats intoxicated with the drug. Acute intoxication does not entail any modification of the sites. On the other hand, binding sites were dramatically decreased by a chronic intoxication realized twice a week. In such a case, this decrease may be directly related to CLQ concentration in the heart. The regulation mechanisms involved are discussed.
Asunto(s)
Cloroquina/envenenamiento , Miocardio/metabolismo , Receptores Nicotínicos/efectos de los fármacos , Animales , Canales de Calcio , Cloroquina/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Nitrendipino/metabolismo , Ratas , Ratas EndogámicasRESUMEN
Immune-mediated hemolytic disease is a phenomenon rarely encountered with cancer chemotherapeutic agents. Elliptinium, a tetracyclic ammonium compound used in breast and kidney cancer, can induce antibodies that may result in clinical hemolysis. This study reports the characterization of the elliptinium haptenic determinant by use of two different methodologies: a hemagglutination test and a radioimmunoassay. Binding of 12 analogues or derivatives of elliptinium was also studied. Good correlation between the two methods was obtained, indicating that the determinant is most likely located on the quaternary ammonium-containing ring. Furthermore, the hydrophilicity of the drug appears to be an important factor in the antibody reaction. The mechanism of the binding of elliptinium to its antibodies is discussed.
Asunto(s)
Alcaloides/inmunología , Anticuerpos/aislamiento & purificación , Antineoplásicos/inmunología , Elipticinas/inmunología , Formación de Anticuerpos , Prueba de Coombs , Reacciones Cruzadas , Detergentes/inmunología , Epítopos , Haptenos/inmunología , Pruebas de Hemaglutinación , Humanos , Radioinmunoensayo , Relación Estructura-Actividad , Tensoactivos/inmunologíaRESUMEN
A method is described for the radioiodination of human calcitonin using the Iodogen reagent. The tracer was purified by 2 successive gel filtrations. The first, using Sephadex G-10, resulted in the complete removal of free 125iodide as assessed by ascending paper chromatography. The second, involving Sephadex G-75, permitted the separation of the tracer from high molecular weight aggregates. Analytical RP-HPLC showed a slight proportion (13%) of a contaminating product, probably (sulfoxyl-methionine9)calcitonin. The final yield, after radioiodination, was found to be 42.7 +/- 5.5% and the tracer displayed a specific activity of 850 +/- 110 Ci/mmol. The effects of long-term storage of the frozen tracer were studied.
Asunto(s)
Calcitonina/metabolismo , Radioisótopos de Yodo/metabolismo , Marcaje Isotópico/métodos , Trazadores Radiactivos , Radioisótopos , Urea/análogos & derivados , Cromatografía en Gel , Cromatografía Líquida de Alta Presión , Cromatografía en Papel , Humanos , Oxidación-ReducciónRESUMEN
Drug-dependent antibodies were investigated in patients treated with elliptinium acetate, a cytostatic drug with activity in advanced breast cancer. Retrospective analysis of 83 patients, receiving weekly intravenous elliptinium, showed a high incidence of anti-elliptinium antibodies (20%). Hemolysis occurred among antibody-positive patients, apparently related to the antibody titer. The predictability of anti-elliptinium antibodies for hemolysis and the schedule dependency of antibody development was examined prospectively. Among 42 patients treated weekly for at least three courses, 40% developed antibodies. Of 30 patients receiving elliptinium daily for three days every three weeks, none developed either antibodies or hemolysis. Only antibody positive patients, with titers greater than or equal to 32 were at risk for hemolysis. The possible mechanisms are discussed.
Asunto(s)
Alcaloides/inmunología , Anemia Hemolítica/inducido químicamente , Anticuerpos/análisis , Elipticinas/inmunología , Anemia Hemolítica/inmunología , Neoplasias de la Mama/tratamiento farmacológico , Elipticinas/efectos adversos , Femenino , Humanos , Estudios Prospectivos , Estudios Retrospectivos , RiesgoRESUMEN
Ellipticine derivatives or analogues, tetracyclic alkaloids used in human cancer treatment, have been evaluated with regard to their interaction with several neurotransmitter receptors, in order to explain or to predict the side effects which occur in man. These drugs were recently found to be reversible non-competitive inhibitors of cholinesterases. In this study, we have shown that ellipticines are also potent muscarinic antagonists, only 100-fold less active than atropine in inhibiting 50% of the specific binding of (3H) quinuclidinyl benzilate on rat brain preparation of muscarinic receptors. That the interaction with muscarinic receptors is quite unique has been demonstrated by the lack of interaction with three other neurotransmitter receptors. Tertiary amines show relatively less blockade of muscarinic receptors, while substituted ammonium ions are better inhibitors of the QNB binding. The possible mechanisms of in vivo action of these alkaloids is discussed.
Asunto(s)
Alcaloides/farmacología , Elipticinas/farmacología , Receptores Muscarínicos/efectos de los fármacos , Animales , Masculino , Ratas , Ratas Endogámicas , Receptores Adrenérgicos beta/efectos de los fármacos , Receptores Nicotínicos/efectos de los fármacosRESUMEN
Binding studies conducted on membrane preparation from human platelets using (3H) Ro5-4864 and (3H) diazepam showed specific and saturable binding. Scatchard analysis revealed a single class of binding sites with KD = 10.8 +/- 0.9 nM and Bmax = 775 +/- 105 fmol/mg protein for (3H) Ro5-4864 and KD = 10.5 +/- 1.1 nM and Bmax = 133 +/- 19 fmol/mg for (3H) diazepam. We were unable to detect any GABA binding site on crude membrane preparation, nor did GABA enhance the binding of (3H) Ro5-4864 or (3H) diazepam. This suggests that benzodiazepine receptors are uncoupled to GABA system on human platelets. Ro15-1788, a specific antagonist for "central type" benzodiazepine (BDZ) binding sites was inactive in displacing (3H) Ro5-4864 from membrane receptors, while PK 11195 (a specific ligand for the "peripheral type" receptor) was the most potent of the drugs tested in inhibiting (3H) Ro5-4864 binding. These results indicate that human blood platelets bear "peripheral-type" BDZ receptor. Moreover, we could not detect any (3H) propyl beta carboline specific binding on platelet membranes. Results on benzodiazepine receptors on human circulating lymphocytes are also reported and similarity in pharmacological properties with platelet benzodiazepine receptors is suggested.
Asunto(s)
Benzodiazepinas/sangre , Plaquetas/metabolismo , Receptores de GABA-A/metabolismo , Benzodiazepinonas/sangre , Unión Competitiva , Membrana Celular/metabolismo , Convulsivantes/sangre , Diazepam/sangre , Humanos , Cinética , Linfocitos/metabolismoRESUMEN
In our experiments on acutely lead exposed rats we observed a marked increase (a 2-fold or 3-fold increase with 30 mg/kg or 60 mg/kg lead acetate, respectively) in [3H]quinuclidinyl benzilate [( 3H]QNB) specific binding to muscarine receptors from striatum and cortex, without any change in receptor affinity. Muscarine receptor level was maximal 2 h after intoxication, but the effect of lead on [3H]QNB binding was completely reversible in 24 h, without any lead redistribution to other brain areas being observed during this time period. Modulation of muscarine receptors in rat brain during in vivo acute intoxication might be involved in some of the observed neurotoxic effects of lead, resulting of an action on cholinergic neurotransmission. The various possible mechanisms of the lead effect on [3H]QNB binding are discussed.
Asunto(s)
Química Encefálica/efectos de los fármacos , Intoxicación por Plomo/metabolismo , Compuestos Organometálicos , Receptores Muscarínicos/efectos de los fármacos , Enfermedad Aguda , Animales , Corteza Cerebral/metabolismo , Cuerpo Estriado/metabolismo , Relación Dosis-Respuesta a Droga , Plomo/metabolismo , Masculino , Quinuclidinil Bencilato , Ratas , Ratas EndogámicasRESUMEN
Binding studies conducted with [3H]Ro 5-4864, a specific ligand for peripheral-type benzodiazepine receptors, on circulating lymphocytes from 5 normal volunteers provided evidence for a single, saturable (Bmax 12.2 +/- 3.6 fmol/10(6) cells), and high affinity (KD 7.1 +/- 2.0 nM) specific binding site. We were unable to detect any GABA receptor, suggesting that human lymphocytes bear a peripheral-type benzodiazepine binding site not coupled with the GABA system. Results on lymphocytes from chronic lymphocytic leukemics are also reported.